Inspections resulted from a report of failure in the supply of medicinal products in particular Ozempic and Trulicity and Freestyle medical device for the self-monitoring of glycaemia, according to Infarmed.
Inspections resulted from a report of failure in the supply of medicinal products in particular Ozempic and Trulicity and Freestyle medical device for the self-monitoring of glycaemia, according to Infarmed.
Infarmed carried out, in 2025, 89 inspections after reporting errors in the provision of medicines for diabetes, resulting in 19 participations to the Department of Public Health for suspicion of overfacing the SNS and 27 co-ordination processes.
Infarmed detected several irregularities in the pharmaceuticals. In addition to medicines also used for weight loss, inspection covered glycaemia measurement devices sought by athletes.